N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(MORPHOLIN-4-YLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE
Star0
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(MORPHOLIN-4-YLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE
- DrugBank Accession Number
- DB07520
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 482.493
Monoisotopic: 482.16108885 - Chemical Formula
- C19H26F4N4O4S
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UCathepsin S Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- Aralkylamines / Fluorobenzenes / Organosulfonamides / Aryl fluorides / Organic sulfonamides / Morpholines / Sulfonyls / Secondary carboxylic acid amides / Oxacyclic compounds / Azacyclic compounds show 9 more
- Substituents
- Alkyl fluoride / Alkyl halide / Alpha-amino acid amide / Amine / Aralkylamine / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid show 31 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- organofluorine compound, monocarboxylic acid amide, sulfonamide, morpholines (CHEBI:41259)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- BJIKKEHGGYGGIX-HOTGVXAUSA-N
- InChI
- InChI=1S/C19H26F4N4O4S/c20-14-3-1-13(2-4-14)16(19(21,22)23)25-15(17(28)26-18(12-24)5-6-18)11-32(29,30)27-7-9-31-10-8-27/h1-4,15-16,25H,5-12,24H2,(H,26,28)/t15-,16-/m0/s1
- IUPAC Name
- (2R)-N-[1-(aminomethyl)cyclopropyl]-3-(morpholine-4-sulfonyl)-2-{[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]amino}propanamide
- SMILES
- [H][C@@](CS(=O)(=O)N1CCOCC1)(N[C@@]([H])(C1=CC=C(F)C=C1)C(F)(F)F)C(=O)NC1(CN)CC1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 11840930
- PubChem Substance
- 99443991
- ChemSpider
- 10015435
- ZINC
- ZINC000016052054
- PDBe Ligand
- C28
- PDB Entries
- 2ft2
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.569 mg/mL ALOGPS logP 0.8 ALOGPS logP 0.062 Chemaxon logS -2.9 ALOGPS pKa (Strongest Acidic) 12.94 Chemaxon pKa (Strongest Basic) 9.22 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 113.76 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 107.33 m3·mol-1 Chemaxon Polarizability 42.97 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9623 Blood Brain Barrier + 0.7676 Caco-2 permeable - 0.6763 P-glycoprotein substrate Substrate 0.705 P-glycoprotein inhibitor I Inhibitor 0.6547 P-glycoprotein inhibitor II Non-inhibitor 0.9902 Renal organic cation transporter Non-inhibitor 0.8813 CYP450 2C9 substrate Non-substrate 0.7778 CYP450 2D6 substrate Non-substrate 0.7999 CYP450 3A4 substrate Non-substrate 0.533 CYP450 1A2 substrate Non-inhibitor 0.8711 CYP450 2C9 inhibitor Non-inhibitor 0.6402 CYP450 2D6 inhibitor Non-inhibitor 0.72 CYP450 2C19 inhibitor Non-inhibitor 0.6308 CYP450 3A4 inhibitor Inhibitor 0.6659 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8627 Ames test Non AMES toxic 0.5898 Carcinogenicity Non-carcinogens 0.8031 Biodegradation Not ready biodegradable 0.9812 Rat acute toxicity 2.5780 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9281 hERG inhibition (predictor II) Inhibitor 0.6153
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0000900000-16bcf171e45bc8bc88e1 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-01q9-0000900000-e806777f244fc2dfa0a8 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0f89-1006900000-9d3f8d61a8ae1e02a682 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0gx0-2324900000-b2fc716a367064adccc7 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-05i0-4941700000-6289aa761dd2d65d7cba Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0400-9651800000-123c5f684b827aad3b1e Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 202.19597 predictedDeepCCS 1.0 (2019) [M+H]+ 204.59154 predictedDeepCCS 1.0 (2019) [M+Na]+ 210.50421 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsCathepsin S
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Thiol protease. Key protease responsible for the removal of the invariant chain from MHC class II molecules and MHC class II antigen presentation (PubMed:30612035). The bond-specificity of this proteinase is in part similar to the specificities of cathepsin L
- Specific Function
- collagen binding
- Gene Name
- CTSS
- Uniprot ID
- P25774
- Uniprot Name
- Cathepsin S
- Molecular Weight
- 37495.49 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:23 / Updated at June 12, 2020 16:52